Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QH 104

Next Previous
Drug Profile

QH 104

Alternative Names: Allogenic B7H3-targeting CAR-γδT cell therapy - Unicet Biotech; QH-104

Latest Information Update: 20 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unicet Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 13 Feb 2025 Peking University plans a early phase I (phase 0) trial for Solid tumors (Late-stage disease, Second-line therapy or greater) in China (IV) in March 2025 (NCT06825455)
  • 20 Jan 2025 Dushu Lake Hospital Affiliated to Soochow University terminates a phase I/II trial in Glioblastoma (Second-line therapy or greater, Recurrent) in China (Intrathecal) due to the trial cannot be continued for the time being due to the renovation of the hospital premises (NCT06018363)
  • 13 Sep 2024 Efficacy and adverse events data from a phase I/II trial in Glioblastoma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top